Epac1 and lung scarring in idiopathic pulmonary fibrosis
Role of Epac1 in the Pathogenesis of Pulmonary Fibrosis
['FUNDING_R01'] · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · NIH-11397242
Looks at whether blocking a protein called Epac1 can reduce lung scarring in people with idiopathic pulmonary fibrosis.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11397242 on ClinicalTrials.gov |
What this research studies
If you have IPF, this project is looking at a protein called Epac1 that is higher in damaged lungs and lung cells from patients. Researchers will use patient lung tissue and cells, along with mouse models of lung fibrosis, to see how Epac1 drives scarring. They will test a drug called AM-001 that specifically blocks Epac1 in lab and animal experiments to see if scarring and harmful cell changes are reduced. The goal is to find whether Epac1 could become a new target for future treatments for people with IPF.
Who could benefit from this research
Good fit: Ideal candidates would be people diagnosed with idiopathic pulmonary fibrosis who can provide lung tissue or cells or who may be eligible for future clinical testing of Epac1-targeting therapies.
Not a fit: People without IPF or those with very advanced respiratory failure are unlikely to benefit directly from this preclinical-focused work.
Why it matters
Potential benefit: If successful, this work could point to a new way to slow or reverse lung scarring in IPF and lead to future drug testing in patients.
How similar studies have performed: Targeting cAMP pathways has shown promise in lab studies, but selectively blocking Epac1 with AM-001 is a newer approach with preclinical support in heart models and limited testing so far in lung disease.
Where this research is happening
NEW YORK, UNITED STATES
- ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HADRI, LAHOUARIA — ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- Study coordinator: HADRI, LAHOUARIA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.